IperionX Lifts Titanium Powder Capacity to 200 Tonnes — but the Balance Sheet Is Still Waiting for Its First Dollar

IperionX closed up 5.1% in Frankfurt, but fiscal 2026 brought zero revenue and a USD 66.8 million net loss as B. Riley cut its target.

IperionX shares closed Friday's session in Frankfurt at EUR 1.54, up 5.1%, a modest bounce with no fresh company-specific catalyst behind it. The move lands against a bruising year for the stock, which has shed 51% since January, and it leaves the equity roughly 11% above its 52-week low.

For a company trying to redraw how titanium powder is made — a material that aerospace, defense, and advanced manufacturing cannot do without, yet whose conventional processing is notoriously power-hungry and costly — the real test is not playing out on the ticker. It is unfolding on the factory floor in Virginia and in the columns of its financial statements.

Virginia Throughput Rises Without New Capital Outlay

Midweek brought the operational headline: through process improvements, IperionX raised the nominal capacity of its Virginia site from 125 tonnes of titanium powder per year to approximately 200 tonnes per year. Management said the increase came without additional capital expenditure.

The company is now targeting an annualized production rate of about 200 tonnes per year by the end of calendar 2026, contingent on successful commissioning and continued optimization of operations. The technical case — that titanium powder can be produced more efficiently and at greater volume — is taking shape. What remains unresolved is how quickly that output converts into contracted offtake.

Full-Year Loss Doubles as Revenue Stays at Zero

The flip side arrived with Wednesday's fiscal 2026 results. IperionX booked no revenue at all for the year. Its net loss widened to USD 66.8 million, compared with a shortfall of USD 35.3 million in fiscal 2025. Cash and cash equivalents stood at USD 35.2 million as of June 30, 2026.

The drivers are straightforward: capacity construction, heavy research and development spending, and the operational ramp-up all consume substantial resources before a single dollar of product revenue can be booked. Against last year's burn rate, management has little choice but to keep the pace of the ramp-up high. Without a timely turn toward operating income, the question of further financing will inevitably return to the agenda.

B. Riley Trims Its Target, Keeps Its Rating

The financial trajectory prompted a more cautious read from the sell side. On Wednesday, September 30, B. Riley Securities cut its price target to USD 34 from USD 52 while reaffirming a Buy rating. Analyst Fedor Shabalin pointed to an unexpectedly large second-half loss, revenue recognition that has slipped, and development costs running above expectations.

The sizable reduction notwithstanding, the firm is sticking with its recommendation — a signal of underlying confidence in the long-term potential, paired with an acknowledgment that the road to first revenues demands more time and capital than previously assumed.

A String of Setbacks Preceded Friday's Gain

The recent advance follows a stretch of news that weighed on the quote. Roughly three weeks ago, the company reported progress on GenX titanium production, and the stock gave up 8.2% in response. A U.S. Army order dates back about a month; since that announcement, the shares have cumulated a decline of 20.3%.

Whether Friday's uptick marks the start of a durable recovery hinges on execution. Investors are watching how swiftly IperionX can turn its expanded Virginia capacity into dependable revenue streams — and whether the 200-tonne annual rate targeted for the end of 2026 proves technically reachable and commercially meaningful, marking the shift from development-stage hopeful to viable supplier. Should that transition land, a fundamental re-rating could follow. Until then, the stock remains a highly volatile gauge of the risk inherent in industrial pioneering.